Your browser doesn't support javascript.
loading
Coverage of Two-Dose Preemptive Cholera Mass Vaccination Campaign in High-Priority Hotspots in Shashemene, Oromia Region, Ethiopia.
Park, Se Eun; Gedefaw, Abel; Hailu, Dejene; Jeon, Yeonji; Mogeni, Ondari D; Jang, Geun Hyeog; Mukasa, David; Mraidi, Ramzi; Kim, Deok Ryun; Getahun, Tomas; Mesfin Getachew, Edlawit; Yeshitela, Biruk; Ayele Abebe, Samuyel; Hussen, Mukemil; Worku Demlie, Yeshambel; Teferi, Mekonnen.
Affiliation
  • Park SE; Clinical, Assessment, Regulatory, Evaluation (CARE) Unit, International Vaccine Institute, Seoul, Republic of Korea.
  • Gedefaw A; Department of Global Health and Disease Control, Yonsei University Graduate School of Public Health, Seoul, Republic of Korea.
  • Hailu D; Clinical, Assessment, Regulatory, Evaluation (CARE) Unit, International Vaccine Institute, Seoul, Republic of Korea.
  • Jeon Y; College of Medicine and Health Sciences, Hawassa University, Hawassa, Ethiopia.
  • Mogeni OD; Clinical, Assessment, Regulatory, Evaluation (CARE) Unit, International Vaccine Institute, Seoul, Republic of Korea.
  • Jang GH; School of Public Health, College of Medicine and Health Sciences, Hawassa University, Hawassa, Ethiopia.
  • Mukasa D; Clinical, Assessment, Regulatory, Evaluation (CARE) Unit, International Vaccine Institute, Seoul, Republic of Korea.
  • Mraidi R; Clinical, Assessment, Regulatory, Evaluation (CARE) Unit, International Vaccine Institute, Seoul, Republic of Korea.
  • Kim DR; Biostatistics and Data Management (BDM) Department, International Vaccine Institute, Seoul, Republic of Korea.
  • Getahun T; Biostatistics and Data Management (BDM) Department, International Vaccine Institute, Seoul, Republic of Korea.
  • Mesfin Getachew E; Biostatistics and Data Management (BDM) Department, International Vaccine Institute, Seoul, Republic of Korea.
  • Yeshitela B; Biostatistics and Data Management (BDM) Department, International Vaccine Institute, Seoul, Republic of Korea.
  • Ayele Abebe S; Clinical Trials Directorate, Armauer Hansen Research Institute, Addis Ababa, Ethiopia.
  • Hussen M; Clinical Trials Directorate, Armauer Hansen Research Institute, Addis Ababa, Ethiopia.
  • Worku Demlie Y; Bacterial and Viral Disease Research Directorate, Armauer Hansen Research Institute, Addis Ababa, Ethiopia.
  • Teferi M; Data Science Division, Armauer Hansen Research Institute, Addis Ababa, Ethiopia.
Clin Infect Dis ; 79(Supplement_1): S33-S42, 2024 Jul 12.
Article in En | MEDLINE | ID: mdl-38996035
ABSTRACT

BACKGROUND:

Cholera is a public health priority in Ethiopia. The Ethiopian National Cholera Plan elaborates a multi-year scheme of oral cholera vaccine (OCV) use. Aligned with this, a preemptive OCV campaign was conducted under our Ethiopia Cholera Control and Prevention project. Here, we present the OCV vaccination outcomes.

METHOD:

Cholera high-priority hotspots in the Oromia Region, Shashemene Town (ST) and Shashemene Woreda (SW), were selected. Four kebelles (Abosto, Alelu, Arada, and Awasho) in ST and 4 clusters (Faji Gole, Harabate, Toga, and Chabi) in SW were study sites with OCV areas nested within. A total of 40 000 and 60 000 people in ST and SW, respectively, were targeted for a 2-dose OCV (Euvichol-Plus) campaign in 11-15 May (first round [R1]) and 27-31 May (second round [R2]) 2022. Daily administrative OCV coverage and a coverage survey in 277 randomly selected households were conducted.

RESULTS:

The administrative OCV coverage was high 102.0% for R1 and 100.5% for R2 in ST and 99.1% (R1) and 100.0% (R1) in SW. The coverage survey showed 78.0% (95% confidence interval [CI] 73.1-82.9) of household members with 2-dose OCV and 16.8% (95% CI 12.4-21.3) with no OCV in ST; and 83.1% (95% CI 79.6-86.5) with 2-dose OCV and 11.8% (95% CI 8.8-14.8) with no OCV in SW. The 2-dose coverages in 1-4-, 5-14-, and ≥15-year age groups were 88.3% (95% CI 70.6-96.1), 88.9% (95% CI 82.1-95.7), and 71.3% (95% CI 64.2-78.3), respectively, in ST and 78.2% (95% CI 68.8-87.7), 91.0% (95% CI 86.6-95.3), and 78.7% (95% CI 73.2-84.1) in SW.

CONCLUSIONS:

High 2-dose OCV coverage was achieved. Cholera surveillance is needed to assess the vaccine impact and effectiveness.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Cholera Vaccines / Cholera / Mass Vaccination Limits: Adolescent / Adult / Child / Child, preschool / Female / Humans / Infant / Male / Middle aged Country/Region as subject: Africa Language: En Journal: Clin Infect Dis Journal subject: DOENCAS TRANSMISSIVEIS Year: 2024 Type: Article

Full text: 1 Database: MEDLINE Main subject: Cholera Vaccines / Cholera / Mass Vaccination Limits: Adolescent / Adult / Child / Child, preschool / Female / Humans / Infant / Male / Middle aged Country/Region as subject: Africa Language: En Journal: Clin Infect Dis Journal subject: DOENCAS TRANSMISSIVEIS Year: 2024 Type: Article